Azithromycin in one week quadruple therapy for H pylori eradication in Iran

Table 1 Clinical and demographic data of patients in the treatment groups

Data	B-OAM-2 wk regimen n (%)	B-OAzM-1 wk regimen n (%)	P value¹
ITT analysis	71	58
Age: yr, Mean (SD)	48.3 (7.4)	46.7 (5.4)	0.17
Male	45 (63.3)	33 (56.8)	0.45
NSAID users	21 (29.5)	15 (25.8)	0.63
Cigarette smokers	11 (15.4)	8 (13.7)	0.78
Abdominal pain	47 (66.1)	31 (53.4)	0.14
Heartburn	14 (19.7)	18 (31)	0.13
Dyspepsia	57 (80.2)	40 (68.9)	0.13
PU	37 (52.1)	25 (43.1)	0.3
Non-ulcer dyspepsia	34 (47.8)	33 (56.8)	0.3
Loss to follow up	2	1
Poor compliance	3	2
Drop-outs	5	3
PP analysis	66	55

¹t; for means and χ² for proportions, ITT; intention to treat, PP; per protocol.

Table 2 Complications of drugs in H pylori treatment

Complication	B-OAM-2 wk regimen	B-OAzM-1 wk regimen	P value²
n	69³	57³
Diarrhea (%)	4 (5.7)	4 (7)
Vomiting (%)	5 (7.2)¹	4 (7)¹
Abdominal pain (%)	7 (10.1)	5 (8.7)
Bad taste (%)	7 (10.1)	5 (8.7)
Anal pain (%)	0	2 (3.5)
Total (%)	23 (33.3%)	20 (35%)	0.83

¹Three patients of group "A" and two patients of group "B" excluded from the study for severe vomiting.; ²χ²; ³ All patients except lost to follow up cases.